NEW HOPE, Pa.--(BUSINESS WIRE)--Protalex, Inc. (OTCBB: PRTX) announced today that the U.S. Patent and Trademark Office (USPTO) has issued a patent for the company’s lead drug, PRTX-100, filed on April 10, 2002 titled “Protein A Compositions and Methods of Use”. The patent covers the use of PRTX-100 in treating Rheumatoid Arthritis (RA), Juvenile Arthritis, Lupus, and other antibody mediated acute inflammatory conditions.
